# Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/axitinib-versus-placebo-as-an-adjuvant-treatment-of-renal-cell-carcinoma-results/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Marine Gross‐Goupil,Tae‐Geon Kwon,Masatoshi Eto,Dingwei Ye,Hideaki Miyake,S.I. Seo,S.-S. Byun,Jia-Lin Lee,Viraj A. Master,Jie Jin,R. DeBenedetto,R. Linke,Michelle Casey,Brad Rosbrook,Mariajosé Lechuga,Olga Valota,Enrique Grande,David I. Quinn |
| Citations | 260 |
| DOI | 10.1093/annonc/mdy454 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.annalsofoncology.org/article/S0923753419342413/pdf |
| OpenAlex ID | https://openalex.org/W2896175597 |
| PMID | 30346481 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Masatoshi Eto](https://scholariq.org/researchers/masatoshi-eto/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.